MedTrace Logo

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

NCT04655911 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2022-05-31

No results posted yet for this study

Summary

This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 years post-treatment).

Conditions

  • Mucopolysaccharidosis III-B

Interventions

BIOLOGICAL

ABO-101

Gene therapy rAAV9.CMV.hNAGLU

Sponsors & Collaborators

  • Abeona Therapeutics, Inc

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2022-04-07
Completion
2022-04-07
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04655911 on ClinicalTrials.gov